|

Ziftomenib Clinical Trials

10 actively recruiting trials across 6 locations

▲ +1 trial since August 2026

Also known as: KO 539, KO-539, KO539, Menin-KMT2A Inhibitor KO 539, Menin-MLL Inhibitor KO-539 +2 more

Pipeline

Phase 1: 6Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Kura Oncology, Inc.4
  • M.D. Anderson Cancer Center2
  • Uma Borate1
  • Tanja Andrea Gruber1
  • Massachusetts General Hospital1

Indications

  • Cancer10
  • Acute Myeloid Leukemia6
  • NPM1 Mutation3
  • KMT2Ar2
  • AML With Mutated NPM12

Gilbert, Arizona2 trials

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Banner MD Anderson Cancer Center

Phase 1
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona2 trials

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Mayo Clinic - Phoenix

Phase 1
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Phoenix Children's Hospital

Phase 1/2

Houston, Texas2 trials

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

MD Anderson Cancer Center

Phase 1
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 1

Other1 trial

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Phase 2

Birmingham, Alabama1 trial

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

University of Alabama at Birmingham

Phase 1

Boston, Massachusetts1 trial

Ziftomenib Maintenance Post Allo-HCT

Massachusetts General Hospital

Phase 1

Columbus, Ohio1 trial

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.